



TOM PULLES, MD

Passionate, mature leader, entrepreneurial-minded professional

✉ tompulles@gmail.com 📞 +41786643931 📍 Wilbrunnen 10, 6314 Unterägeri, Switzerland

Profile

Over 20 years' experience of matrix strategic leadership and coaching within the Healthcare industry, of which more than a decade in Rare Diseases, in Global & Regional Medical Affairs & Strategy, Clinical Development, Medical Education, Patient Advocacy & Engagement . A flexible, creative, and strategic team leader with entrepreneurial spirit, high ethical standards and a strong sense of purpose. Great interpersonal communication, and decision-making leadership skills with the ability to influence, motivate, and inspire others through a coaching-style leadership and can-do attitude.

Education

- Masters Medicine** Sep 1992 – Nov 1999
Utrecht University, Utrecht, NL
- Bachelors Medicine** Sep 1991 – Jul 1992
Erasmus University, Rotterdam, NL

Employment

- Consultant, Chief Medical Officer (CMO)** Jun 2022 – Present
Khondrion, Nijmegen, NL
 - Oversee planning, coordination, and execution of Clinical Development and Early Access Programmes in Rare Primary Mitochondrial Disorders
 - Engage with Scientific Advisory Board, Principle Investigators, and Patient Advocacy Groups to discuss clinical programmes
- EMEA Regional Head of Medical Affairs & Patient Advocacy** Sep 2017 – May 2022
Ultragenyx Pharmaceutical, Allschwil, CH
 - Build, expand, and manage the European Medical (field) teams, Medical Affairs Operations & Capabilities, incl. Clinical Trial support, Medical Information & Communications, and Grants across Rare Disease Portfolio (incl. Neuromuscular – GNEM, FAOD, DMD; Metabolic – GSD, OTC, MPS)
 - Oversee development and execution of the EMEA regional medical-scientific affairs strategy and budget in line with global medical, commercial, clinical development, and full portfolio strategy, including Gene Therapies, Protein Biologics, Small

I consent to the processing of my personal data for the purpose of recruitment for the position to which I am applying.

Personal details

LinkedIn
linkedin.com/in/tom-pulles-md-9b39384

Skills

- Communication
- Leadership
- Entrepreneurial
- Strategic Thinking

Languages

- Dutch
- English
- German
- French

Hobbies

- Family
- Outdoor Sports
- Nature

Molecules, and ASO/mRNA.

- Lead the Regional (pre)launch team as well as the Regional Investigator Sponsored Trials, Early Access Programme and Grants Review Committee.
- Provide strategic Regional input and support of ongoing clinical development programmes across the full portfolio, including Regional CT site recommendations, feasibility, patient diagnostic and recruitment activities as well as Disease Monitoring Programmes and Phase IV studies.
- Standing member of the EMEA Leadership Team as well as (co)chair or member of several global cross-functional sub-teams.
- Provide strategic medical and scientific input into due diligence activities for new business developments and geographical expansion opportunities.
- Actively participate in national payer and health authorities' interactions and discussions with Market Access and Regulatory Affairs colleagues.
- Provide strategic medical insights and expertise to Commercial organization to compliantly ensure the development and execution of commercial strategy and related activities.
- Forge and enhance strong relationships and collaboration with relevant EMEA Key Medical Experts, Patient Associations and Advocacy Groups.

EU Regional Head of Patient Advocacy & Public Affairs Nov 2016 – Aug 2017

Ultragenyx Pharmaceutical, Basel, CH

- Develop and execute the EU Patient Advocacy and Public Affairs strategy & plans, including full budget planning, tracking and execution responsibilities in close collaboration and communication with local country colleagues.
- Manage interactions with International Patient Associations, Patient Advocacy Groups, & Public Affairs bodies.
- Forge and enhance strong compliant partnerships and collaboration with EU Patient Advocacy Groups.
- Provide strategic input and scientific support to Global Franchise Teams, Clinical Development & Operations to ensure the patient and caregiver voice is incorporated for successful programme activities, protocol development & execution of ongoing clinical trials programmes across the company Rare Diseases portfolio.
- Standing member of the EMEA Leadership Team as well as member of several global cross-functional sub-teams.

Founding Partner & Co-owner, Healthcare Coaching & Consulting Aug 2016 – Present
Diima GmbH, Unterägeri, CH

Sr. Global Therapeutic Area Head, Rare Diseases Mar 2014 – Jul 2016
Shire Pharmaceuticals, Zug, CH

Global Medical Director, Human Genetic Therapies Oct 2012 – Mar 2014
Shire Pharmaceuticals, Nyon, CH

International Medical Director, Nephrology & Hematology Shire Pharmaceuticals, Nyon, CH	Jan 2011 – Sep 2012
Medical Director MEDCON International, Heemstede, NL	Oct 2006 – Dec 2010
Country Medical Manager, Cardiometabolic Disorders sanofi aventis, Gouda, NL	Jan 2004 – Sep 2006
Medical Advisor Cardiovascular Solvay Pharma, Weesp, NL	Mar 2002 – Dec 2003
Military Physician Royal Netherlands Navy, Den Helder, Rotterdam, NL	Jan 2000 – Mar 2002

Internships

Residency General Medicine Royal Netherlands Navy, Curacao, Dutch Antilles	Aug 1999 – Nov 1999
Residency Gynecology & Obstetrics Mowbray Maternity Hospital, Cape Town, SA	Nov 1998 – Feb 1999

Courses

Changing Employees Behavior IMD Business School, Lausanne, CH	2021
Advanced High-Performance Leadership IMD Business School, Lausanne, CH	2019
Being Innovative & Strategic Thinking IMD Business School, Lausanne, CH	2018
High Performance Leadership IMD Business School, Lausanne, CH	2017
Health Care Compliance Leadership Programme INSEAD, Fontainebleau, France	2010

Publications

- **Ten years of the Hunter Outcome Survey (HOS): insights, achievements, and lessons learned from a global patient registry.** Orphanet Journal of Rare Diseases; May 2017.
- **Birth weight in patients with mucopolysaccharidosis type II: Data from the Hunter Outcome Survey (HOS).** Molecular Genetics and Metabolism Reports; May 2017.

- Development of a Measure to Assess Severity of MPS II: the Disease Severity Score. Value Health. Nov 2015.
 - Lessons learned in updating a large global registry to achieve long-term improvements in data completeness and quality: the Hunter Outcome Survey moving towards system enhancement (HOSMOSE) project. Molecular Genetics and Metabolism; Feb 2014.
-

Extracurricular activities

President

Nov 2021 – Present

Touch Rugby Switzerland

References

References available upon request.